Denver, CO (PRWEB) February 24, 2016
It has been observed and demonstrated that Reward Deficiency Syndrome (RDS) is the one of the underlying causes of addiction. RDS sufferers have a genetic predisposition toward addiction. Science has shown that these individuals have a brain disorder whereby the neurons that are responsible for pleasurable feelings are lacking compared to a normally-functioning brain. Sadly, as the specific neurons tend to lack in dopamine production, many RDS sufferers turn to drugs, which stimulate the production of dopamine that the body would generally receive through a normal brain.
It is thought that this condition reflects roughly 1/3 of the world's population. RDS generally manifests as anxiety, cravings, and depression. The resulting dopamine deficiency has been linked as a major cause of depression, and is a fundamental aspect of treating addiction. A new therapy has emerged, specifically geared to treat dopamine deficiency: Third Generation Genetic Recovery System (TGGRS).
AminoKit Laboratories, the leading treatment for this TGGRS amino acid therapy, has shown tremendous success in treating RDS, the underlying cause of many drug addictions. This therapy consists of intravenously supplanting the amino acids responsible for dopamine production. Therefore, the body is able to produce the average amount of dopamine. Once TGGRS amino acid therapy is employed, and the underlying lack of dopamine in the brain is addressed, we have found the RDS in the suffering patient is substantially reduced.
AminoKit Laboratories has itself treated many RDS sufferers successfully using this groundbreaking amino acid therapy. AminoKit Laboratories reports an unbelievable success ration when treating RDS with TGGRS amino acid therapy, when in combination with psychotherapy, education classes, massage therapy, and other treatment modalities. We have found that Reward Deficiency Syndrome is effectively treated with TGGRS amino acid therapy, and thus these innovative treatment centers—like AminoKit Laboratories—will continue to thrive.